{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03346967",
      "OrgStudyIdInfo": {
        "OrgStudyId": "VinmecRISCGT72"
      },
      "Organization": {
        "OrgFullName": "Vinmec Research Institute of Stem Cell and Gene Technology",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone Deficiency",
      "OfficialTitle": "Evaluation of Autologous Adipose Derived Mesenchymal Stem Cells (AD-MSCs) Therapy on Sexual Hormone Deficiency in the Middle-aged Patients: an Open-label, Single-group Clinical Trial",
      "Acronym": "MSCSHD"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 1, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "February 28, 2020",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 30, 2020",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 14, 2017",
      "StudyFirstSubmitQCDate": "November 14, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 20, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 21, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 26, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Vinmec Research Institute of Stem Cell and Gene Technology",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and effectiveness of adipose derived mesenchymal stem cells (AD-MSCs) therapy on sexual hormone deficiency in the middle-aged patients",
      "DetailedDescription": "The purpose of this study is to evaluate the safety and efficiency of adipose-derived mesenchymal stem cells in 30 patients with sexual hormone deficiency at Vinmec International Hospital, Hanoi, Vietnam"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Hormone Deficiency"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "AD mesenchymal stem cells;sexual hormone deficiency"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "30 patients with sexual hormone deficiency will be injected AD-MSCs",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Stem cell Administration for female patients",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Combination Product: adipose-derived mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Stem cell Administration for male patients",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Combination Product: adipose-derived mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Combination Product",
            "InterventionName": "adipose-derived mesenchymal stem cells",
            "InterventionDescription": "Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Stem cell Administration for female patients",
                "Stem cell Administration for male patients"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Serum levels of follicle-stimulating hormone (FSH), Anti-Mullerian Hormone (AMH) and estradiol (E2) for female and testosterone level for male",
            "PrimaryOutcomeDescription": "Comparison between Serum levels of follicle-stimulating hormone (FSH), Anti-Mullerian Hormone (AMH) and estradiol (E2) for female and testosterone level for male at pre and post AD-MSCs therapy",
            "PrimaryOutcomeTimeFrame": "up to the 12-month period following treatment"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge: 35 years to 70 years (Male) and from 35 years to menopause age (Female)\nMale: decrease in libido, decrease in intercourse frequency, erectile dysfunction, Difficulty in concentration, testosterone level ≤ 12 nMol/dL\nFemale: reduced or absent menstruation after radiation exposure or chemotherapy; Hot flushes, excessive sweating, and anxiety, together with other symptoms associated with the menopause, AMH level ≤ 2 ng/ml and/or FSH level ≥ 10 mIU/ml.\nPatients signed the informed consent form\n\nExclusion Criteria:\n\nSurgery removal of endocrine glands\nAbnormalities in the endrocrine glands\nHormone deficiency due to diabetes and other metabolic disorders\nActive autoimmune diseases\nCurrent usage of immunosuppressive drugs\nCoagulation disorders\nAllergy to anesthetic agents\nSevere health conditions such as cancer, failure of heart, lung, liver or kidney\nActive infections",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "GenderBased": "Yes",
      "GenderDescription": "40 years to 65 years (Male) and from 40 years to menopause age (Female)\nMale: decrease in libido, decrease in intercourse frequency, erectile dysfunction, Difficulty in concentration, testosterone level ≤ 12 nMol/dL\nFemale: reduced or absent menstruation after radiation exposure or chemotherapy; Hot flushes, excessive sweating, and anxiety, together with other symptoms associated with the menopause, AMH level ≤ 2 ng/ml and/or FSH level ≥ 10 mIU/ml.",
      "MinimumAge": "35 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Liem Nguyen, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(+84 4) 3 974 3556",
            "CentralContactPhoneExt": "1420",
            "CentralContactEMail": "v.liemnt@vinmec.com"
          },
          {
            "CentralContactName": "Phuong Nguyen, MPH",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(+84) 914740683",
            "CentralContactEMail": "hoangphuonghsph@gmail.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Liem Nguyen, PhD",
            "OverallOfficialAffiliation": "Vinmec Healthcare System",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Vinmec Research Institute of Stem Cell and Gene Technology",
            "LocationStatus": "Recruiting",
            "LocationCity": "Hanoi",
            "LocationZip": "10000",
            "LocationCountry": "Vietnam",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Phuong Nguyen, MPH",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "(+84)914740683",
                  "LocationContactEMail": "hoangphuonghsph@gmail.com"
                },
                {
                  "LocationContactName": "Liem Nguyen, Prof",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "28053944",
            "ReferenceType": "result",
            "ReferenceCitation": "Reed-Maldonado AB, Lue TF. The Current Status of Stem-Cell Therapy in Erectile Dysfunction: A Review. World J Mens Health. 2016 Dec;34(3):155-164. doi: 10.5534/wjmh.2016.34.3.155. Epub 2016 Dec 22. Review."
          },
          {
            "ReferencePMID": "27077129",
            "ReferenceType": "result",
            "ReferenceCitation": "Haahr MK, Jensen CH, Toyserkani NM, Andersen DC, Damkier P, Sørensen JA, Lund L, Sheikh SP. Safety and Potential Effect of a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial. EBioMedicine. 2016 Jan 19;5:204-10. doi: 10.1016/j.ebiom.2016.01.024. eCollection 2016 Mar."
          },
          {
            "ReferencePMID": "25811565",
            "ReferenceType": "result",
            "ReferenceCitation": "Charles-de-Sá L, Gontijo-de-Amorim NF, Maeda Takiya C, Borojevic R, Benati D, Bernardi P, Sbarbati A, Rigotti G. Antiaging treatment of the facial skin by fat graft and adipose-derived stem cells. Plast Reconstr Surg. 2015 Apr;135(4):999-1009. doi: 10.1097/PRS.0000000000001123."
          },
          {
            "ReferencePMID": "34129158",
            "ReferenceType": "derived",
            "ReferenceCitation": "Nguyen Thanh L, Dam PTM, Nguyen HP, Nguyen TT, To HM, Nguyen HB, Luu NA, Hoang DM. Can Autologous Adipose-Derived Mesenchymal Stem Cell Transplantation Improve Sexual Function in People with Sexual Functional Deficiency? Stem Cell Rev Rep. 2021 Dec;17(6):2153-2163. doi: 10.1007/s12015-021-10196-w. Epub 2021 Jun 15."
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000004700",
            "ConditionMeshTerm": "Endocrine System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafAsFound": "Hormone Deficiency",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M8941",
            "InterventionBrowseLeafName": "Hormones",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}